Table 1. Patient demographics, by nodal status and Recurrence Score assay status (N=241,681).
Category | Parameter |
Node-negative, HR+ (N=184,190) |
Node-positive (N+(mic,1-3))a, HR+ (N=57,491) |
||
---|---|---|---|---|---|
HER2− With RS (N=40,134) | HER2±b Without RS (N=144,056) | HER2− With RS (N=4,691) | HER2±b Without RS (N=52,800) | ||
n (%) | n (%) | n (%) | n (%) | ||
Age | <40 years | 1,480 (3.7) | 4,827 (3.4) | 165 (3.5) | 3,889 (7.4) |
40–49 years | 9,350 (23.3) | 21,492 (14.9) | 853 (18.2) | 12,513 (23.7) | |
50–59 years | 12,744 (31.8) | 31,230 (21.7) | 1,375 (29.3) | 14,032 (26.6) | |
60–69 years | 11,913 (29.7) | 35,676 (24.8) | 1,418 (30.2) | 11,536 (21.8) | |
70–79 years | 4,173 (10.4) | 30,548 (21.2) | 778 (16.6) | 6,952 (13.2) | |
⩾80 years | 474 (1.2) | 20,283 (14.1) | 102 (2.2) | 3,878 (7.3) | |
Sex | Male | 235 (0.6) | 999 (0.7) | 34 (0.7) | 559 (1.1) |
Female | 39,899 (99.4) | 143,057 (99.3) | 4,657 (99.3) | 52,241 (98.9) | |
Race | White | 33,684 (83.9) | 119,790 (83.2) | 4,021 (85.7) | 42,723 (80.9) |
Black | 2,890 (7.2) | 11,539 (8.0) | 328 (7.0) | 5,357 (10.1) | |
Other | 3,321 (8.3) | 11,940 (8.3) | 320 (6.8) | 4,434 (8.4) | |
Unknown | 239 (0.6) | 787 (0.5) | 22 (0.5) | 286 (0.5) | |
Tumor sizec | ⩽5 mm | 1,281 (3.2) | 20,601 (14.6) | 142 (3.0) | 1,393 (2.7) |
>5–10 mm | 8,724 (21.9) | 36,005 (25.5) | 689 (14.8) | 4,339 (8.4) | |
>10–20 mm | 21,100 (52.9) | 51,530 (36.5) | 2,332 (50.0) | 19,036 (36.7) | |
>20–40 mm | 7,847 (19.7) | 26,521 (18.8) | 1,271 (27.2) | 20,078 (38.7) | |
>40 mm | 914 (2.3) | 6,465 (4.6) | 233 (5.0) | 7,030 (13.6) | |
Tumor gradec | Well | 11,208 (28.8) | 44,742 (32.9) | 1,333 (29.0) | 8,525 (16.8) |
Moderate | 21,035 (54.0) | 62,320 (45.8) | 2,517 (54.8) | 25,334 (50.1) | |
Poord | 6,704 (17.2) | 28,888 (21.2) | 742 (16.2) | 16,742 (33.1) | |
Reported CT use | No/unknown | 31,023 (77.3) | 112,008 (77.8) | 3,048 (65.0) | 17,258 (32.7) |
Yes | 9,111 (22.7) | 32,048 (22.2) | 1,643 (35.0) | 35,542 (67.3) |
Abbreviations: CT, chemotherapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; RS, Recurrence Score result.
Excludes patients with ⩾4 positive nodes or unknown/missing nodal status.
Excludes patients with HER2-positive breast cancer in cohorts with Recurrence Score results, based on 21-gene assay quantitative single-gene HER2 result (by reverse transcription-PCR); includes patients with HER2-positive breast cancer in cohorts without Recurrence Score results because HER2 status was not reported to SEER before 2010.
Among patients in the cohort with nonmissing information.
Includes undifferentiated and anaplastic tumors.